Inhibiting the Aggregation of Aβ by Natural Product Molecules

Abstract

The abnormal aggregation of Aβ has been considered one of the primary causative factors for Alzheimer’s disease. Diverse molecular entities have been developed to mitigate the formation of toxic Aβ aggregates within the brain by inhibiting Aβ aggregation. Recognizing that many FDA‐approved drugs are derived from natural products, we present a summary of recent discoveries involving natural product molecules with inhibitory effects on Aβ aggregation. By consolidating these findings, our review offers researchers a concise overview of the latest advancements in natural product‐based interventions for Alzheimer's disease.